On October 13, 2021 Prescient Therapeutics (PTX) reported that it will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California (Press release, Prescient Therapeutics, OCT 13, 2021, https://themarketherald.com.au/prescient-therapeutics-asxptx-to-present-new-omnicar-data-at-conference-2021-10-13/?utm_source=rss&utm_medium=rss&utm_campaign=prescient-therapeutics-asxptx-to-present-new-omnicar-data-at-conference [SID1234591210]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference brings together senior executives and decision makers on therapies including cell therapy.

OmniCAR is a universal immune receptor platform allowing controllable T-cell activity and multi-antigen targeting with a single cell product.

The most recent work with the Peter MacCallum Cancer Centre showed that OmniCAR-T cells begin antigen-directed killing of tumour cells in vitro as soon as they are armed.

It was also discovered that OmniCAR-T cells could be re-armed and continue to kill tumour cells without loss of cytotoxicity.

These new results show the important capabilities of OmniCAR to deliver next generation cell therapies that are controllable and able to target multiple cancer antigens.

Prescient’s Director of Scientific Affairs Rebecca Lim is pleased with the new results.

"Excitingly, we saw for the first time the real-time ‘switchability’ of the OmniCAR system where the tumour killing ability of the OmniCAR-T cells could be redirected towards a different antigen through the addition of a different binder," Dr Lim said.

"These early wins are extremely encouraging, and we look forward to the next phase
of pre-clinical testing where the OmniCAR technology will be put through its paces using gold standard cancer models."

Dose response
A dose response relationship is the correlation between the amount of drug given the magnitude of response. Normally, higher doses lead to greater effects.

In cell therapies such as CAR-T therapy, where living cells that continue to grow and divide are administrated to patients, effects are considerably less predictable and controllable.

The aim of OmniCAR is to combine the potent cytotoxicity of cell therapy with the control and predictability of a conventional drug.

Prescient treated glioblastoma multiforme (GBM) cells with OmniCAR-T cells armed with varying amounts of SpyTagged EGFRviii and Her2 binders to test whether different doses of binders resulted in equal levels of CAR-T activity.

In both cases, OmniCAR showed dose-dependent tumour killing activity, with the ability to control OmniCAR-T cell activity.

Re-arming
Single infusions of CAR-T cells may be insufficient to drive meaningful patient outcomes in many cancers, especially solid tumours.

Prescient has now shown this "re-arming" capability of OmniCAR. OmniCAR-T cells pre-armed with Her2 binders demonstrated potent ability to kill cancer cells extracting Her2. Following this, the cells were washed and rested for several days, resulting in unarmed OmniCAR cells.

These same OmniCAR-T cells were then capable of being re-armed with Her2 binders, and once again showed the same results.

"This demonstrates that OmniCAR cells can be unarmed, re-armed and still kill with near identical fidelity. It is another example of the flexible yet predictable activity of OmniCAR cells," the company said.

Managing Director and CEO Steven Yatomi-Clarke is looking forward to present this data at the Cell & Gene Meeting this week.

"It is very pleasing to see a large body of work accomplished successfully so quickly and is a credit to the Prescient team and the incredible collaborators at Peter MacCallum Cancer Centre," he said.

"Importantly, none of these tests have even been optimised, so we have yet to see the true limits of this technology. OmniCAR is proving to be a predictable and powerful system to work with. We look forward to sharing updates as our programs progress."

On the market this morning, Prescient was up 9.09 per cent and is trading at 24 cents per share at 11:40 am AEDT.

On October 13, 2021 Compass, Inc. (NYSE: COMP), a leading real estate technology company, reported that its third quarter 2021 financial results will be released after market close on Wednesday, November 10, 2021 (Press release, Compass Therapeutics, OCT 13, 2021, View Source [SID1234591199]). The company will host a conference call and webcast to discuss its results that afternoon at 4:30 p.m. ET / 1:30 p.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Call details are as follows:

The conference call will be accessible via the Internet on the Compass Investor Relations website, View Source

Please register in advance to access the live conference call at: Compass Inc. 3Q21 Earnings Conference Call.

An audio recording of the conference call will be available for replay shortly after the call’s completion for up to 90 days following the call. To access the replay, visit the Events and Presentations section of the Compass Investor Relations website.

On October 13, 2021 Geneseeq Technology Inc. ("Geneseeq") and Zai Lab, Ltd. ("Zai Lab") (Nasdaq: ZLAB)(HKEX: 9688) reported that new strategic collaboration in Shanghai, China (Press release, Zai Laboratory, OCT 13, 2021, View Source [SID1234591198]). The companies will collaborate to facilitate the R&D and commercialization of Zai Lab’s cancer drugs through business partnerships in clinical trial patient recruitment, central laboratory testing, companion diagnostics development and marketing activities . The announcement was made at the Zai Lab Innovation Summit on October 12th in Shanghai.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Marc Zhao, the co-founder and Chief Operating Officer of Geneseeq delivered a keynote speech on the landscape of gastrointestinal tumor detection and diagnosis during the conference. To conclude, Zhao said that Geneseeq and Zai Lab hope to use this strategic collaboration as the cornerstone to combine resources of both companies to provide high-quality cancer diagnostics and treatment solutions. I look forward to further joint actions between the two parties to improve cancer patient outcomes and generate positive societal impact.

William Liang , Chief Commercial Officer of Zai Lab and President of Greater China said: "In recent years, advances in genetic testing technology have boosted the continuous improvement of precision medicine and treatment programs. Zai Lab has three products listed in China with 10-15 more products expected to be approved. Many of them rely on biomarker testing. We hope to work with genetic testing partners to help patients achieve precise and personalized treatment. At the same time, we also look forward to working with these partners to improve the efficiency of drug research and development, shorten the development cycle, and accelerate product approvals."

The companies look forward to a strong alliance in providing more accurate and efficient treatment plans for patients.

On October 13, 2021 Illumina, Inc. (NASDAQ:ILMN) reported that it will issue results for the third quarter 2021 following the close of market on Thursday, November 4, 2021 (Press release, Illumina, OCT 13, 2021, View Source [SID1234591197]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, November 4, 2021. Interested parties may access the live teleconference through the Investor Info section of Illumina’s website under the "company" tab at www.illumina.com. Alternatively, individuals can access the call by dialing 1 (844) 200-6205 or 1 (929) 526-1599 outside North America, both with Conference ID 808648. To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following.

On October 13, 2021 IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, reported that it has entered into an At-The-Market Distribution Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC, as sole sales agent (the "Agent") (Press release, ImmunoPrecise Antibodies, OCT 13, 2021, View Source [SID1234591196]). Under the ATM Agreement, the Company will be entitled, at its discretion and from time-to-time during the term of the ATM Agreement, to sell, through the Agent common shares of the Company (the "Common Shares") having an aggregate gross sales price of up to US$50 million (the "Offering" or "ATM Facility"). Sales of the Common Shares will be made in transactions that are deemed to be "at-the-market offerings" as defined in Rule 415 of the United States Securities Act of 1933, as amended, and "at-the-market distributions" as defined in National Instrument 44-102 – Shelf Distributions, including, without limitation, sales made directly on the Nasdaq Global Market or any other existing trading market for the Common Shares in the United States. No offers or sales of Common Shares will be made in Canada on the TSX Venture Exchange (the "TSXV") or other trading markets in Canada.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will determine, at its sole discretion, the date, minimum price and maximum number of Common Shares to be sold under the ATM Facility. The Common Shares will be distributed from time to time in negotiated transactions, at market prices prevailing at the time of sale, at prices relating to such prevailing market prices, and/or in any other manner permitted by applicable law. As such, the prices may vary between purchasers over time. The Company is not required to sell any Common Shares at any time during the term of the ATM Facility.

The Company intends to use the net proceeds of the Offering, if any and at the discretion of the Company, to support the growth and development of the Company’s existing operations as well as working capital and general corporate purposes. The Company will pay the Agent a cash fee for Common Shares sold under the ATM Agreement and will reimburse certain expenses incurred by the Agent.

The TSXV has conditionally approved the listing of the Common Shares distributed in the Offering, and the Nasdaq Global Market has been notified of the Offering.

The Offering will be made by way of a prospectus supplement dated October 13, 2021 (the "Prospectus Supplement") to the Company’s existing Canadian short form base shelf prospectus dated December 11, 2020 (the "Base Shelf Prospectus") and U.S. registration statement on Form F-10, as amended (File No. 333-249957), dated January 5, 2021 (the "Registration Statement"). The Registration Statement was declared effective by the United States Securities and Exchange Commission (the "SEC") on January 11, 2021. The Prospectus Supplement has been filed with the British Columbia Securities Commission and the SEC. The ATM Agreement, the Prospectus Supplement and the related Base Shelf Prospectus are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Alternatively, the Agent will send the documents upon request by contacting the Agent: H.C. Wainwright & Co., LLC, 430 Park Avenue 3rd Floor, New York, NY 10022, telephone: (646) 975-6996, email: [email protected]. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.